Latest Breaking News On - Wolframcm dempke - Page 1 : comparemela.com

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

HOUSTON, May 16, 2024 /PRNewswire/ Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today.

Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

Moleculin Biotech (MBRX) Appoints Wolfram C. M. Dempke as European Chief Medical Officer